An Update on the Roles of the Complement System in Autoimmune Diseases and the Therapeutic Possibilities of Anti-Complement Agents
December 2010
in “
Current Drug Therapy
”
Studysummary This review discusses the role of complement activation in autoimmune diseases and explores the potential for anti-complement therapies as a new treatment strategy, without reporting new clinical results. Our plain-language summary of this paper — not a Tressless recommendation.
The document discussed the critical role of complement activation in innate immunity and its potential to cause tissue damage when unregulated, contributing to autoimmune diseases like rheumatoid arthritis, lupus nephritis, and Guillain-Barre syndrome. Traditional therapies for these diseases included corticosteroids and immunosuppressive agents, while newer biological response modifiers such as anti-TNF and anti-IL6 agents showed promise but had severe side effects. The review highlighted the potential of anti-complement agents as an alternative therapeutic strategy to control autoimmune diseases, suggesting that regulating the complement system could offer a new approach to treatment.
